BUZZ — Biotech co Alector rises after premium — priced $75 mln stock sale

* Biotech firm Alector's shares up 6.8% at $2.04 before the bell on Fri after $75 mln follow-on priced * ALEC sells 36.6 mln shares at $2.05, 7.3% above their last sale on Thurs * Financing includes participation from new and existing investors, including TCGX, BVF Partners, among others, co says * It intends to use net offering proceeds for general purposes, including R&D, working capital, capex, expenses, potential acquisitions * Morgan Stanley and BTIG joint bookrunners * On Oct 5, ALEC's stock ultimately finished session up ~10% at $1.99 after it announced that Genentech, a unit of Swiss drugmaker Roche, will pay up to $1.27 bln to license AL050, ALEC's experimental drug for Parkinson's disease * South San Francisco, California-based ALEC has ~111.7 mln shares outstanding * At Thurs close, stock up 30% over the past three months (Lance Tupper is a Reuters market analyst. The views expressed are his own) ((lance.tupper@tr.com 1-646-279-6380)